Overview Dividends

(DOCS) Doximity - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US26622P1075

Collaboration, Scheduling, Telehealth, Documentation, News

DOCS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 29.72%
EPS Trend (3Y Correlation): 91.3%

DOCS Revenue

Revenue Growth (3Y CAGR): 14.81%
Revenue Trend (3Y Correlation): 86.1%

Risk via 10d forecast
Volatility	56.3%
Value at Risk 5%th	74.2%

Reward
Sharpe Ratio	-0.08
Alpha Jensen	-32.26

Character
Hurst Exponent	0.520
Beta	1.360

Drawdowns 3y
Max DD	49.92%
Mean DD	22.43%

Description: DOCS Doximity October 31, 2025

Doximity, Inc. (NASDAQ: DOCS) runs a U.S.-focused digital network that equips physicians, nurse practitioners, physician assistants, medical students, pharmaceutical firms, and health systems with tools for professional collaboration, career management, on-call scheduling, documentation, and virtual patient visits.

Key operating metrics (as of the most recent FY 2023 filing) include roughly 2 million active members and a year-over-year revenue growth rate of about 30 %, driven primarily by pharmaceutical advertising and subscription services for clinical workflow tools. The platform’s telehealth adoption surged during the pandemic, and while growth has moderated, the broader health-care-technology sector remains buoyed by ongoing digitization mandates and reimbursement reforms that favor remote care.

Strategic risks to watch are user-engagement retention (especially as competing networks emerge), regulatory scrutiny over data privacy, and the concentration of revenue in pharma advertising, which could be vulnerable to shifts in marketing spend. Conversely, the expanding need for integrated digital documentation and the rising prevalence of value-based care models create tailwinds for Doximity’s suite of workflow solutions.

For a deeper quantitative assessment of Doximity’s valuation metrics, you may find the ValueRay platform’s analyst toolkit useful.

DOCS Stock Overview

Market Cap in USD	10,221m
Sub-Industry	Health Care Technology
IPO / Inception	2021-06-24
Return 12m vs S&P 500	-24.2%
Analyst Rating	3.68 of 5

DOCS Dividends

Currently no dividends paid

DOCS Growth Ratios

CAGR	16.69%
CAGR/Max DD Calmar Ratio	0.33
CAGR/Mean DD Pain Ratio	0.74
Current Volume	2346.5k
Average Volume	1279.1k

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (253.0m TTM) > 0 and > 6% of Revenue (6% = 37.3m TTM)

FCFTA 0.25 (>2.0%) and ΔFCFTA 5.58pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 153.2% (prev 159.7%; Δ -6.50pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.25 (>3.0%) and CFO 319.7m > Net Income 253.0m (YES >=105%, WARN >=100%)

Net Debt (-158.0m) to EBITDA (269.9m) ratio: -0.59 <= 3.0 (WARN <= 3.5)

Current Ratio 7.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (200.7m) change vs 12m ago 0.17% (target <= -2.0% for YES)

Gross Margin 90.20% (prev 89.94%; Δ 0.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 52.31% (prev 46.21%; Δ 6.10pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -8.88 (EBITDA TTM 269.9m / Interest Expense TTM -28.9m) >= 6 (WARN >= 3)

Altman Z'' 7.86

(A) 0.76 = (Total Current Assets 1.09b - Total Current Liabilities 140.3m) / Total Assets 1.26b

(B) 0.13 = Retained Earnings (Balance) 157.7m / Total Assets 1.26b

(D) 0.99 = Book Value of Equity 159.4m / Total Liabilities 161.6m

Total Rating: 7.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 89.94

1. Piotroski 5.50pt = 0.50

2. FCF Yield 3.36% = 1.68

3. FCF Margin 50.61% = 7.50

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda -0.59 = 2.50

6. ROIC - WACC (= 9.80)% = 12.25

7. RoE 23.90% = 1.99

8. Rev. Trend 86.06% = 6.45

9. EPS Trend 91.25% = 4.56

What is the price of DOCS shares?

As of November 13, 2025, the stock is trading at USD 50.96 with a total of 2,346,470 shares traded.
Over the past week, the price has changed by -20.36%, over one month by -24.50%, over three months by -17.57% and over the past year by -12.21%.

Is Doximity a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Doximity (NYSE:DOCS) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 89.94 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DOCS is around 44.34 USD . This means that DOCS is currently overvalued and has a potential downside of -12.99%.

Is DOCS a buy, sell or hold?

Doximity has received a consensus analysts rating of 3.68. Therefor, it is recommend to hold DOCS.

Strong Buy: 5
Buy: 3
Hold: 11
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DOCS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	70.4	38.2%
Analysts Target Price	70.4	38.2%
ValueRay Target Price	50.6	-0.8%

DOCS Fundamental Data Overview November 11, 2025

Market Cap USD = 10.22b (10.22b USD * 1.0 USD.USD)
P/E Trailing = 43.432
P/E Forward = 47.619
P/S = 16.4506
P/B = 13.1472
P/EG = 2.4191
Beta = 1.36
Revenue TTM = 621.3m USD
EBIT TTM = 256.4m USD
EBITDA TTM = 269.9m USD
Long Term Debt = 12.4m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 2.12m USD (from shortTermDebt, last quarter)
Debt = 11.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -158.0m USD (from netDebt column, last quarter)
Enterprise Value = 9.35b USD (10.22b + Debt 11.3m - CCE 878.4m)
Interest Coverage Ratio = -8.88 (Ebit TTM 256.4m / Interest Expense TTM -28.9m)
FCF Yield = 3.36% (FCF TTM 314.5m / Enterprise Value 9.35b)
FCF Margin = 50.61% (FCF TTM 314.5m / Revenue TTM 621.3m)
Net Margin = 40.72% (Net Income TTM 253.0m / Revenue TTM 621.3m)
Gross Margin = 90.20% ((Revenue TTM 621.3m - Cost of Revenue TTM 60.9m) / Revenue TTM)
Gross Margin QoQ = 90.25% (prev 89.18%)
Tobins Q-Ratio = 7.44 (Enterprise Value 9.35b / Total Assets 1.26b)
Interest Expense / Debt = 34.39% (Interest Expense 3.88m / Debt 11.3m)
Taxrate = 14.92% (10.9m / 72.9m)
NOPAT = 218.2m (EBIT 256.4m * (1 - 14.92%))
Current Ratio = 7.79 (Total Current Assets 1.09b / Total Current Liabilities 140.3m)
Debt / Equity = 0.01 (Debt 11.3m / totalStockholderEquity, last quarter 1.10b)
Debt / EBITDA = -0.59 (Net Debt -158.0m / EBITDA 269.9m)
Debt / FCF = -0.50 (Net Debt -158.0m / FCF TTM 314.5m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.13% (Net Income 253.0m / Total Assets 1.26b)
RoE = 23.90% (Net Income TTM 253.0m / Total Stockholder Equity 1.06b)
RoCE = 23.94% (EBIT 256.4m / Capital Employed (Equity 1.06b + L.T.Debt 12.4m))
RoIC = 20.85% (NOPAT 218.2m / Invested Capital 1.05b)
WACC = 11.05% (E(10.22b)/V(10.23b) * Re(11.03%) + D(11.3m)/V(10.23b) * Rd(34.39%) * (1-Tc(0.15)))
Discount Rate = 11.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.07%
[DCF Debug] Terminal Value 72.35% ; FCFE base≈275.6m ; Y1≈340.0m ; Y5≈580.2m
Fair Price DCF = 44.37 (DCF Value 6.10b / Shares Outstanding 137.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 91.25 | EPS CAGR: 29.72% | SUE: 2.36 | # QB: 8
Revenue Correlation: 86.06 | Revenue CAGR: 14.81% | SUE: 2.30 | # QB: 2

Additional Sources for DOCS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle